SPOTLIGHT -
EP. 1: Dr. Mikhael on Treatment Selection for Early Relapse in Multiple Myeloma
Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.
EP. 2: Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma
Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.
EP. 3: Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma
Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.
EP. 4: Treatment Considerations in Relapsed/Refractory Multiple Myeloma
EP. 5: Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma
Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.
EP. 6: Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma
Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.
EP. 7: Dr. Martin on the Utility of CAR T-Cell Therapy in Late Relapsed Multiple Myeloma
Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.
in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg
ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma
Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer
%20copy.png?fit=crop&auto=format)
